Twist Bioscience Corp vs Vanguard Value Index Fund ETF — how do they compare? Twist Bioscience Corp trades at $154.2 (market cap $10.08B), while Vanguard Value Index Fund ETF trades at $219.98 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 26× Twist Bioscience Corp's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| TWST | VTV | |
|---|---|---|
Market Cap | $10.08B | $262.40B |
Volume | 4,229,037 | 3,293,281 |
Sector | Health | — |
52-Week High | $205.00 | $227.51 |
52-Week Low | $25.45 | $182.86 |
Typical Hold Time | 27 Days | 142 Days |
Enterprise Value | $10.01B | — |
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Vanguard Value ETF (VTV) trades at $218.21, down 0.35% on the day amid a bearish technical signal. The ETF shows neutral momentum oscillators but bearish moving averages, with key support at $217 and resistance at $219. Recent institutional buying by QRG Capital Management and Blue Edge Capital reflects confidence in value strategies, while news highlights VTV's 2.3% dividend yield and outperformance versus growth ETFs in 2026.
VTV offers exposure to large-cap value stocks with a low 0.03% expense ratio, appealing for income and stability. Risks include prolonged underperformance versus growth sectors and market rotation sensitivity. Analyst sentiment is mixed, balancing dividend appeal against broader market trends. The ETF remains a core holding for value-focused portfolios amid economic uncertainty.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →